Page 2 - Vitro Diagnostics News Today

Surmodics (NASDAQ:SRDX – Get Free Report)‘s stock had its “neutral” rating reiterated by research analysts at Sidoti in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $43.00 price objective on the stock. Sidoti’s price objective points to a potential upside of 2.09% from the company’s current price. Other equities […]

Surmodics (NASDAQ:SRDX – Get Free Report)‘s stock had its “hold” rating reaffirmed by stock analysts at Lake Street Capital in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $43.00 target price on the stock. Lake Street Capital’s price target points to a potential upside of 2.14% from the company’s […]

Vitro Diagnostics (OTCMKTS:VODG – Get Free Report) and Innate Pharma (NASDAQ:IPHA – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability. Profitability This table compares Vitro Diagnostics and Innate […]

02 May, 2024 Immunovias pancreatic cancer test to further boost IVDs role in early disease detection, says GlobalData Share ...

Surmodics (NASDAQ:SRDX – Free Report) had its price objective lowered by Needham & Company LLC from $47.00 to $43.00 in a report released on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. Separately, StockNews.com downgraded Surmodics from a strong-buy rating to a buy rating in a report on Wednesday, […]

Surmodics (NASDAQ:SRDX – Get Free Report) announced its earnings results on Wednesday. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.43, Zacks reports. The business had revenue of $31.96 million during the quarter, compared to analyst estimates of $28.79 million. Surmodics had a net margin […]

CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific Ltd, 2024. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE...

Regulatory News: The Eurofins network of companies continues to deliver resilient growth: Reported revenues in Q1 2024 totalled €1,653m, an increase of 5.0% vs Q1 2023, driven by solid...

StockNews.com upgraded shares of Surmodics (NASDAQ:SRDX – Free Report) from a buy rating to a strong-buy rating in a research report sent to investors on Tuesday. Separately, Needham & Company LLC reissued a buy rating and set a $47.00 target price on shares of Surmodics in a research report on Wednesday, April 10th. View Our […]